<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01699074</url>
  </required_header>
  <id_info>
    <org_study_id>182629</org_study_id>
    <nct_id>NCT01699074</nct_id>
  </id_info>
  <brief_title>Acute Dose Response of Korean White Ginseng in Metabolic Syndrome or Type 2 Diabetes</brief_title>
  <acronym>KWG</acronym>
  <official_title>Acute Dose Response Effects of Korean White Ginseng (Panax Ginseng C.A. Meyer) on Cardiovascular Disease Risk Factors in Individuals With Metabolic Syndrome or Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <brief_summary>
    <textblock>
      The study is a Phase-I like double blind randomized placebo controlled crossover design
      trial. The objective is to assess the dose response relationship on glycemic and vascular
      effects of an acutely administered Korean White Ginseng (KWG)(Panax C.A. Meyer) in
      individuals with metabolic syndrome or type 2 diabetes . Twenty seven subjects with Type 2
      Diabetes (Key inclusion criteria: HbA1c ≤8.5%)or metabolic syndrome (Key inclusion criteria:
      as defined by The US National Cholesterol Education Program Adult Treatment Panel III)will be
      recruited for the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study hypothesizes that KWG will dose dependently lower postprandial area under the
      curve compared to negative control, as well as will dose dependently decrease postprandial
      glycemia. It also assumes that use of KWG will dose dependently decrease aortic and brachial
      blood pressure, aortic augmentation index, and mean arterial pressure, and improve left
      ventricular ejection duration(ED) and subendocardial viability ratio (SEVR) compared to
      control. Finally, it expects to notice an effect on subjective satiety levels and have no
      significant adverse effects compared to control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of KWG on vascular and glycemic measures</measure>
    <time_frame>3 hours</time_frame>
    <description>To evaluate the acute dose response effect of KWG on blood glucose Area under the Curve (AUC) compared to controls in individuals with Metabolic syndrome or Type 2 Diabetes To evaluate the acute effect of KWG treatments on arterial stiffness as measured by aortic augmentation index (AIx)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of KWG on vascular and glycemic measures</measure>
    <time_frame>4 hours</time_frame>
    <description>To evaluate the acute effect of Korean White ginseng treatments on peak and postprandial glycemia measures.To evaluate the acute effect of KWG treatments on aortic and brachial blood pressure To evaluate the acute effect of KWG treatments on heart rate, mean arterial pressure, left ventricular ejection duration (ED) and subendocardial viability ratio (SEVR) - a surrogate marker of myocardial perfusion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>KWG and satiety</measure>
    <time_frame>4 hours</time_frame>
    <description>To evaluate the acute effect of KWG treatments on subjective satiety scores to determine any potential effects on appetite control mechanisms compared to controls. Symptoms questionnaire will assess potential adverse effects of treatments (safety)</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>1 gram of White Korean Ginseng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 gram of White Korean Ginseng</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 grams of White Korean Ginseng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 grams of White Korean Ginseng</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 grams of White Korean Ginseng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 grams of White Korean Ginseng</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 grams of Wheat Bran Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 grams of Wheat Bran Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500mg of Korean Red Ginseng</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500mg of Korean Red Ginseng</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>1 gram of White Korean Ginseng</intervention_name>
    <description>1 gram of White Korean Ginseng</description>
    <arm_group_label>1 gram of White Korean Ginseng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>3 grams of White Korean Ginseng</intervention_name>
    <description>3 grams of White Korean Ginseng</description>
    <arm_group_label>3 grams of White Korean Ginseng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>6 grams of White Korean Ginseng</intervention_name>
    <description>6 grams of White Korean Ginseng</description>
    <arm_group_label>6 grams of White Korean Ginseng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>3 grams of Wheat Bran Control</intervention_name>
    <description>3 grams of Wheat Bran Control</description>
    <arm_group_label>3 grams of Wheat Bran Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>500mg of Korean Red Ginseng</intervention_name>
    <description>500mg of Korean Red Ginseng</description>
    <arm_group_label>500mg of Korean Red Ginseng</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women

          -  18-75 years old

          -  BMI 25-35 kg/m2

          -  Presence of type 2 diabetes (as defined by HbA1c ≤8.5%),treatment with diet or oral
             hypoglycemic medication) OR

          -  Presence of Metabolic Syndrome as defined by The US National Cholesterol -Education
             Program Adult Treatment Panel III (NCEP III). As per NCEP III criteria, at least three
             of the following must be present:

          -  central obesity: waist circumference ≥ 102 cm or 40 inches (male), ≥ 88 cm or 36
             inches(female)

          -  dyslipidemia: TG ≥ 1.7 mmol/L (150 mg/dl);

          -  dyslipidemia: HDL-C &lt; 40 mg/dL (male), &lt; 50 mg/dL (female) blood pressure ≥ 130/85
             mmHg; fasting plasma glucose ≥ 6.1 mmol/L (110 mg/dl)

        Exclusion Criteria:

          -  BMI &gt;35 kg/m2

          -  Hypertensive (brachial systolic BP ≥140mmHg and/or diastolic BP ≥90mmHg)

          -  Pregnant women, or those at risk of pregnancy, or breastfeeding at the time of the
             study.

          -  Women of childbearing age that do not use acceptable method of birth control (ie.
             abstinence, implants, injectables, oral contraceptives, IUDs etc).

          -  Chronic conditions including: liver disease, cancer, heavy alcohol use, bleeding
             disorders, history of angina, congestive heart failure, coronary revascularization,
             peripheral vascular disease, retinopathy, kidney disease or coronary/cerebrovascular
             event; chronic use of medications including blood-thinners, SSRIs, MAO inhibitors,
             medications affecting NO synthesis (eg. Viagra)

          -  Allergy or sensitivity to the placebo (wheat bran), ginseng or gelatin used in the
             capsules.

          -  Use of any ginseng products within three days preceding the study and during the
             study.

          -  Allergies to Panax species, their constituents or to other members of the Araliaceae
             family.

        The use of additional NHPs that may affect blood pressure or blood glucose Individuals
        suffering from glucose-galactose malabsorption syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>: Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2012</study_first_submitted>
  <study_first_submitted_qc>October 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2012</study_first_posted>
  <last_update_submitted>April 14, 2014</last_update_submitted>
  <last_update_submitted_qc>April 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Korean White Ginseng</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

